S

Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506

Watchlist Manager
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Watchlist
Price: 186.35 CNY -2.73% Market Closed
Market Cap: 74.7B CNY
Have any thoughts about
Sichuan Biokin Pharmaceutical Co Ltd?
Write Note

Sichuan Biokin Pharmaceutical Co Ltd
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Sichuan Biokin Pharmaceutical Co Ltd
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Long-Term Debt
ÂĄ192.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Long-Term Debt
ÂĄ104.5m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Long-Term Debt
ÂĄ158.1m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
-6%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Long-Term Debt
ÂĄ58.3m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Long-Term Debt
ÂĄ195.6m
CAGR 3-Years
43%
CAGR 5-Years
118%
CAGR 10-Years
42%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Long-Term Debt
ÂĄ425.1k
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Sichuan Biokin Pharmaceutical Co Ltd
Glance View

Market Cap
74.7B CNY
Industry
Pharmaceuticals

Sichuan Biokin Pharmaceutical Co Ltd, nestled in the thriving economic landscape of China, is a dynamic force in the pharmaceutical industry. The company has carved a niche for itself by specializing in the production and commercialization of generic and proprietary drugs. Founded on the principles of innovation and accessibility, Biokin has dedicated its resources to the development of a wide range of pharmacological solutions that address both chronic and acute health conditions. Its state-of-the-art manufacturing facilities are complemented by rigorous research and development wings, where scientists and pharmacists collaborate meticulously to forge products that meet the stringent standards of efficacy and safety. At the heart of Sichuan Biokin's business model lies a commitment to affordability and quality, a combination that has enabled it to secure a significant share of the domestic pharmaceutical market. The company capitalizes on the economies of scale, leveraging its expansive production capabilities to reduce costs and enhance profit margins. By strategically aligning with healthcare providers and distributors, Biokin ensures its products efficiently reach hospitals, clinics, and pharmacies across the nation. This extensive distribution network not only enhances accessibility for patients but also cements Biokin’s reputation as a reliable pharmaceutical partner. Meanwhile, its growing portfolio of consumer healthcare products, alongside ongoing investments in biosimilars and more complex drug formulations, positions Biokin to thrive in the ever-evolving global healthcare arena.

Intrinsic Value
48.32 CNY
Overvaluation 74%
Intrinsic Value
Price
S

See Also

What is Sichuan Biokin Pharmaceutical Co Ltd's Long-Term Debt?
Long-Term Debt
192.6m CNY

Based on the financial report for Dec 31, 2023, Sichuan Biokin Pharmaceutical Co Ltd's Long-Term Debt amounts to 192.6m CNY.

What is Sichuan Biokin Pharmaceutical Co Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 1Y
-34%

Over the last year, the Long-Term Debt growth was -34%.

Back to Top